Insider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells $298,838.67 in Stock

Insmed Incorporated (NASDAQ:INSM) insider Michael Alexander Smith sold 4,407 shares of the company’s stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $67.81, for a total transaction of $298,838.67. Following the transaction, the insider now owns 92,203 shares of the company’s stock, valued at $6,252,285.43. This represents a 4.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Michael Alexander Smith also recently made the following trade(s):

• On Wednesday, May 14th, Michael Alexander Smith sold 409 shares of Insmed stock. The stock was sold at an average price of $65.61, for a total transaction of $26,834.49.

Insmed Trading Up 1.3%

Shares of INSM stock opened at $68.12 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The firm has a market cap of $12.41 billion, a PE ratio of -12.19 and a beta of 0.84. The company has a 50-day moving average of $71.57 and a two-hundred day moving average of $73.12. Insmed Incorporated has a 1-year low of $21.92 and a 1-year high of $84.91.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The company had revenue of $92.82 million for the quarter, compared to analysts’ expectations of $91.63 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The company’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same period last year, the business earned ($1.06) EPS. On average, analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently commented on INSM. Guggenheim reiterated a “buy” rating and issued a $101.00 target price on shares of Insmed in a research report on Tuesday, February 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Insmed in a research report on Wednesday, February 19th. Truist Financial increased their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday, February 21st. Royal Bank of Canada reiterated an “outperform” rating and issued a $100.00 target price on shares of Insmed in a research report on Wednesday, March 19th. Finally, JPMorgan Chase & Co. increased their target price on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $94.63.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of INSM. Park Avenue Securities LLC boosted its stake in Insmed by 42.1% during the fourth quarter. Park Avenue Securities LLC now owns 7,955 shares of the biopharmaceutical company’s stock worth $549,000 after buying an additional 2,358 shares during the period. Atomi Financial Group Inc. lifted its position in shares of Insmed by 6.6% during the fourth quarter. Atomi Financial Group Inc. now owns 24,774 shares of the biopharmaceutical company’s stock worth $1,710,000 after purchasing an additional 1,526 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company’s stock worth $244,000 after purchasing an additional 183 shares in the last quarter. Avior Wealth Management LLC acquired a new stake in shares of Insmed during the fourth quarter worth about $157,000. Finally, Blue Trust Inc. lifted its position in shares of Insmed by 25.7% during the fourth quarter. Blue Trust Inc. now owns 2,462 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 503 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.